<DOC>
	<DOCNO>NCT02702518</DOCNO>
	<brief_summary>The purpose study evaluate tolerability preliminary efficacy rhDNase I eye drop patient ocular Graft-vs.-Host disease ( oGVHD ) .</brief_summary>
	<brief_title>rhDNase Eye Drops Patients With Ocular Graft-Vs.-Host Disease</brief_title>
	<detailed_description />
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>The PI member International Chronic Ocular GVHD Consensus Group establish consensus diagnostic criterion classification chronic ocular GVHD . Table 1 : Severity scale chronic ocular GVHD Severity score ( point ) Schirmer 's test ( mm ) CFS ( point ) OSDI ( point ) Conj ( point ) 0 &gt; 15 0 &lt; 13 None 1 . 1115 &lt; 2 1322 Mild/Moderate 2 . 610 23 2332 Severe 3 . ≤5 ≥4 ≥33 CFS ; corneal fluorescein staining , OSDI ; Ocular Surface Disease Index . Conj ; conjunctival injection . Severity classification ; Total score ( point ) ; ( Schirmer 's test score+ CFS score+ OSDI score+ Conj injection score ) = None ; 04 , Mild/Moderate ; 58 , Severe , 911 . Table 2 : Diagnosis chronic ocular GVHD None ( point ) Probable GVHD ( point ) Definite GVHD ( point ) Systemic GVHD ( − ) 05 67 ≥8 Systemic GVHD ( + ) 03 45 ≥6 Based criterion ( Tables 1 2 ) ,40 patient definite ocular GVHD enrol . Additionally , follow criterion meet eligible study : Aged 18 year old . Capable give informed consent provide inform consent . Schirmer I &lt; 10 Corneal/ conjunctival ( Rose Bengal ) stain ≥1 Ocular symptom must consider annoy activity limiting ( OSDI ≥13 ; mild ) . Women must postmenopausal ≥ 1 year , surgically sterilize . If , negative urine pregnancy test require within 14 day receive first dose test medication ( placebo/ study drug ) along definite evidence contraceptive use duration study . Women reproductive age use method birth control acceptable subject study doctor . This may include oral contraceptive pill , birth control implant , barrier method abstinence . If subject mention suspect may pregnant enrol , another pregnancy test administer . If test positive , discontinue study immediately . Subjects eligible study follow criterion meet : Allergic rhDNase I similar product , recipient rhDNase I eye drop 0.1 % . Receiving receive within 30 day experimental systemic medication . Active ocular infection ocular allergy . Any history eyelid surgery ocular surgery within past 3 month . Corneal epithelial defect large 1 mm2 either eye . Have active drug/alcohol dependence abuse history . Vulnerable population , neonate , pregnant woman , child , prisoner , institutionalized individual , others may consider vulnerable population .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>rhDNase I , Pulmozyme , oGVHD , Dry Eye</keyword>
</DOC>